Neuroimaging data used to construct viable aging biomarker

U.K. and Aussie researchers have introduced a clinically relevant neuroimaging biomarker of aging-related brain deterioration and, in the process, shown how brain age predicts mortality.  

Dr. James Cole of Imperial College London and colleagues had their work published online April 25 in Molecular Psychiatry.

The team analyzed neuroimaging data from 2,001 healthy reference patients to calculate brain age using machine-learning algorithms. They used 669 cases in the Lothian Birth Cohort of 1936 to determine relationships with age-associated functional measures and mortality.

The researchers found that having a brain-predicted age indicative of an older-appearing brain was associated with weaker grip strength, poorer lung function, slower walking speed, lower fluid intelligence, higher allostatic load and increased mortality risk.

What’s more, while combining brain-predicted age with gray matter and cerebrospinal fluid volumes—themselves strong predictors—not did improve mortality risk prediction, the combination of brain-predicted age and DNA-methylation-predicted age did, the authors write.

“This study provides evidence that neuroimaging data can be used to construct a viable aging biomarker, and potentially provides important prognostic information, particularly in combination with complementary epigenetic aging data,” conclude Cole et al. “A global biomarker of aging has the potential to screen for asymptomatic individuals who are experiencing adverse aging and thus are at increased risk of future ill-health and could be used as a surrogate outcome measure in clinical trials of neuroprotective treatments and anti-aging therapeutics.”

The journal has posted the study in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.